摘要
目的:通过成骨细胞体外培养技术,对6种植物黄酮进行对体外骨细胞培养作用的比较研究。方法:采用UMA-106-01成骨细胞株进行成骨细胞培养,观察ALP活性和3H-TdR掺入的情况。结果:24h,培养液中骨碎补总黄酮ALP活性高于对照组。细胞内骨碎补总黄酮、柚皮苷、陈皮苷、淫羊藿总黄酮ALP活性显著增加。48h,培养液中骨碎补总黄酮、淫羊藿总黄酮、菟丝子总黄酮ALP活性高于对照组。细胞内骨碎补总黄酮、淫羊藿总黄酮、菟丝子总黄酮ALP活性显著增加。骨碎补总黄酮、柚皮苷、淫羊藿总黄酮,24h,3H计数显著高于对照组。骨碎补总黄酮、淫羊藿总黄酮、柚皮苷、菟丝子总黄酮、陈皮苷对成骨细胞均有一定作用。结论:6种黄酮类补肾中药对体外培养的成骨细胞,除槲皮素外均有一定的作用,以骨碎补总黄酮作用最为广泛和明显。
AIM：To study the effects of flavonoids extracted from six kinds of Chinese medical drug on osteocytes cultured in vitro compartively by the technology of culturing osteoblasts in vitro. Method ： By culturing UMA-106-01 osteoblast strains to osteoblasts, the activity of ALP and the endosmosis of 3H：TdR were observed. Results ： In 24 hours, the activity of ALP in flavonoids of Rhizoma Drynariae in the culture media was higher than that of control group. The activity of ALP in flavonoids of Rhizoma Drynariae, Naringin, tangerine peel glycoside, fiavonolds of Herba Epimedii and flavonoids of Semen Cuscutae in cells increased significantly. In 48 hours, the activity of ALP in flavonoids of Rhizoma Drynariae, flavonoids of Herba Epimedii and flavonoids of Semen Cuscutae in the culture media was higher than that of control group. The activity of ALP in flavonoids of Rhizoma Drynariae, flavonoids of Herba Epimedii and flavonoids of Semen Cuscutae in cells increased significantly. The numbers of ^3H in flavonoids of Rhizoma Drynariae, Naringin, and flavonoids of Herba Epimedii in 24 hours were much more than those of control groups. All the six kinds of flavonoids （flavonoids of Rhizoma Drynariae, flavonoids of Herba Epimedii, Naringin, flavonoids of Semen Cuscutae, tangerine peel glycoside, quercetin） have certain effects on osteoclasts. Conclusion：The six kinds of flavonoids, except for the quercetin, can increase the activity of osteoblasts cultured in vitro,and among them the effect of osteopractic total flavone is most wide and strong. The effects to osteoclasts still need further studies.
出处
《中国中医基础医学杂志》
CAS
CSCD
北大核心
2005年第9期664-667,共4页
JOURNAL OF BASIC CHINESE MEDICINE
基金
国家"九五"科技攻关重大疾病课题(96-906-09-04)
